428 related articles for article (PubMed ID: 33980166)
1. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine-induced thrombotic microangiopathy with nephrotic syndrome.
Katagiri D; Hinoshita F
CEN Case Rep; 2018 Nov; 7(2):217-220. PubMed ID: 29766468
[TBL] [Abstract][Full Text] [Related]
3. The use of eculizumab in gemcitabine induced thrombotic microangiopathy.
Krishnappa V; Gupta M; Shah H; Das A; Tanphaichitr N; Novak R; Raina R
BMC Nephrol; 2018 Jan; 19(1):9. PubMed ID: 29329518
[TBL] [Abstract][Full Text] [Related]
4. The Detection of Urinary Podocytes from Drug-Induced Glomerular Thrombotic Microangiopathy in Advanced Cancer Patients.
Usui J; Yokoyama C; Hagiwara M; Hirayasu K; Kojima T; Yoshino T; Nishiyama H; Hara M; Yamagata K
Clin Lab; 2016 Dec; 62(12):2413-2417. PubMed ID: 28164557
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-induced thrombotic microangiopathy.
Richmond J; Gilbar P; Abro E
Intern Med J; 2013 Nov; 43(11):1240-2. PubMed ID: 24237646
[TBL] [Abstract][Full Text] [Related]
6. Thrombotic Microangiopathy Following Chemotherapy with S-1 and Cisplatin in a Patient with Gastric Cancer: A Case Report.
Muto J; Kishimoto H; Kaizuka Y; Kinjo M; Higashi H; Kishihara F
In Vivo; 2017; 31(3):439-441. PubMed ID: 28438876
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre.
Grall M; Daviet F; Chiche NJ; Provot F; Presne C; Coindre JP; Pouteil-Noble C; Karras A; Guerrot D; François A; Benhamou Y; Veyradier A; Frémeaux-Bacchi V; Coppo P; Grangé S
BMC Nephrol; 2021 Jul; 22(1):267. PubMed ID: 34284729
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.
Daviet F; Rouby F; Poullin P; Moussi-Francès J; Sallée M; Burtey S; Mancini J; Duffaud F; Sabatier R; Pourroy B; Grandvuillemin A; Grange S; Frémeaux-Bacchi V; Coppo P; Micallef J; Jourde-Chiche N
Br J Clin Pharmacol; 2019 Feb; 85(2):403-412. PubMed ID: 30394581
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine-related thrombotic microangiopathy: a single-centre retrospective series.
Leal F; Macedo LT; Carvalheira JB
J Chemother; 2014 Jun; 26(3):169-72. PubMed ID: 24091354
[TBL] [Abstract][Full Text] [Related]
10. Thrombotic microangiopathy, cancer, and cancer drugs.
Izzedine H; Perazella MA
Am J Kidney Dis; 2015 Nov; 66(5):857-68. PubMed ID: 25943718
[TBL] [Abstract][Full Text] [Related]
11. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma.
Hobeika L; Self SE; Velez JC
BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV
Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655
[TBL] [Abstract][Full Text] [Related]
13. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
[TBL] [Abstract][Full Text] [Related]
14. Quinine-Induced Thrombotic Microangiopathy: A Report of 19 Patients.
Page EE; Little DJ; Vesely SK; George JN
Am J Kidney Dis; 2017 Nov; 70(5):686-695. PubMed ID: 28780041
[TBL] [Abstract][Full Text] [Related]
15. Mild forms of thrombotic microangiopathy in patients with advanced pancreatic cancer receiving gemcitabine and nab-paclitaxel.
Garcia de Herreros M; Esposito F; Sauri T; Font C
J Oncol Pharm Pract; 2023 Apr; 29(3):738-745. PubMed ID: 35876362
[TBL] [Abstract][Full Text] [Related]
16. Microangiopathy associated with gemcitabine: a drug interaction with nab-paclitaxel? A case series and literature review.
Allard J; Bonnet M; Laurent L; Bouattour M; Gagaille MP; Leclerc V
Eur J Clin Pharmacol; 2022 Jul; 78(7):1087-1093. PubMed ID: 35507073
[TBL] [Abstract][Full Text] [Related]
17. Rapid Improvement in Gemcitabine-associated Thrombotic Microangiopathy After a Single Dose of Eculizumab: Case Report and Review of the Literature.
Burns ST; Damon L; Akagi N; Laszik Z; Ko AH
Anticancer Res; 2020 Jul; 40(7):3995-4000. PubMed ID: 32620643
[TBL] [Abstract][Full Text] [Related]
18. Refractory secondary thrombotic microangiopathy with kidney injury associated with systemic lupus erythematosus in a pediatric patient.
Kaneda T; Tanaka E; Akutsu Y; Kanamori T; Mouri M; Morio T; Mori M
CEN Case Rep; 2020 Nov; 9(4):301-307. PubMed ID: 32304042
[TBL] [Abstract][Full Text] [Related]
19. [A case of thrombotic microangiopathy during chemotherapy with gemcitabine in a patient with pancreatic cancer].
Kashima H; Minami R; Ozawa T; Matsumoto A; Kimura Y; Takeda Y; Ueo T; Okano A; Kusumi F; Ohana M
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(3):259-266. PubMed ID: 35264490
[TBL] [Abstract][Full Text] [Related]
20. Thrombotic Microangiopathy in a Patient Treated With Gemcitabine.
Nanjappa S; Singh V; Uttamchandani S; Pabbathi S
Cancer Control; 2017 Jan; 24(1):54-56. PubMed ID: 28178713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
